ERBB2 and breast carcinoma: To overcome the clinical challenges of higher toxicity and instability in the LO enzyme and increase its therapeutic efficacy, the present study was hypothesized to develop a PEGylated chitosan-based enzyme (LO) delivery system for HER2/neu targeted breast cancer therapy.